+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Healthcare-associated Infectious Disease Diagnostics Market - Global Outlook and Forecast 2019-2024

  • ID: 4847025
  • Report
  • Region: Global
  • 290 pages
  • Arizton
UP TO OFF
until Dec 31st 2019
1 of 4

FEATURED COMPANIES

  • Abbott
  • bioMérieux
  • DiaSorin Molecular
  • Hoffmann-La Roche
  • Luminex
  • Quidel
  • MORE

The healthcare-associated infectious disease diagnostics market is expected to grow at a CAGR of over 8% during the period 2018–2024. The growing demand for POC tests for the diagnosis of HAIs will have a positive impact on the growth of the global healthcare-associated infectious disease diagnostics market during the forecast period. The application of molecular diagnostics, especially for HAIs, has steadily progressed from research-based highly complex tests to widespread adoption by a diverse range of end-users. While traditional techniques are being challenged, the development of molecular diagnostic tests offers a variety of advantages such as high accuracy and specificity and perform multiple tests in a single instance. Molecular diagnostics will become a critical part of hospital-acquired infections testing, especially in the battle against antibiotic resistance. Hence, the adoption of molecular diagnostics is likely to increase at a significant rate due to its high sensitivity, specificity, and accuracy, as well as the capability to deliver results quickly. This adoption of molecular diagnostic testing will have a positive impact on the growth of the overall healthcare-associated infectious disease diagnostics market in the coming years.

The following factors are likely to contribute to the growth of the healthcare-associated infections diagnostics market during the forecast period:

  • Growing Penetration of POC Tests for Diagnosing HAIs
  • Strategic Acquisitions
  • Increasing Popularity of Molecular Diagnostic Tests for HAIs
  • Increase in Target Patients with Healthcare-associated Infections

This research report on the global healthcare-associated infectious disease diagnostics market covers sizing and forecast, market share, industry trends, growth drivers, and vendor analysis. The market study includes insights on segmentation by products (consumables and diagnostic analyzers/instruments devices), infections(urinary tract infections, surgical site infections,hospital-acquired pneumonia, bloodstream infections, and other healthcare-associated infections), tests(traditional diagnostics and molecular diagnostics), end-users( hospitals, clinics,ambulatory surgical centers (ASCs), and other end-users), and geography (North America, APAC, Europe, Latin America, and MEA).
The study considers the present scenario of the healthcare-associated infections diagnostics market and its market dynamics for the period 2018−2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply aspects of the market. The report profiles and examines leading companies and other prominent companies operating in the market.

Healthcare-associated Infectious Disease Diagnostics Market: Segmentation

This research report includes detailed market segmentation by products, tests, end-users, infection, and geography. The usage of a wide array of reagents and test kits to perform diagnostic tests for diagnosing several healthcare-associated infectious diseases is a major factor for the growth of the consumables segment. The consumables segment is growing due to the increasing usage of several microbial culture tests, urinalysis, immunoassay tests, and PCR tests in several healthcare settings for diagnosing infectious diseases.

The analyzer segment is growing at a relatively slower pace than the consumables segment as it is capital intensive and purchasing decisions for analyzers depend on financial resources and budget allocations. However, analyzers used in molecular diagnostic tests and at POC sites are growing at a relatively higher growth rate than clinical laboratory analyzers as end-users are preferring analyzers with high sensitivity and delivering highly accurate results with less turnaround time.

Urinary tract infections (UTI) account for 35−40% of all nosocomial infections and occupy the largest share in the overall HAIs category. The prevalence of hospital-acquired UTIs is continuously increasing globally. The market is likely to grow at a CAGR of 9% during the forecast period. The surgical site infections (SSI) segment is growing at a steady rate and is likely to grow at a similar pace during the forecast period. The surgical site infections (SSI) segment is growing at a steady rate and is likely to grow at a similar pace during the forecast period. The prevalence of hospital-acquired pneumonia (HAP) and related deaths is increasing at an alarming rate worldwide. Therefore, there is an increased emphasis on minimizing the occurrence of HAP in healthcare settings. The market is expected to witness fast growth in the coming years due to the development and commercialization of advanced nucleic acid detection tests and advancements in POC testing products for pneumonia.

The traditional diagnostics segment is growing at a moderate rate. A reliable and accurate diagnosis of HAIs is of utmost importance in healthcare settings. Traditional diagnostic tests are considered as the gold-standard and are widely used to diagnose HAIs. The healthcare-associated infectious disease diagnostics market is witnessing widespread uptake of POC diagnostic tests for the diagnosis of several infections in several healthcare settings such as acute and ambulatory healthcare settings. Therefore, there is a growing need for highly efficient and automated diagnostic tests for diagnosing HAIs, especially antibiotic-resistant microbes.

Hospitals are the major source for HAIs, and many hospitalized patients acquire several pathogenic and non-pathogenic infections during the stay. Most hospitals report central line-associated bloodstream infections, catheter-associated UTIs, and SSIs following surgeries such as heart, abdominal hysterectomy, colon, and knee surgical procedures. The adoption of diagnostic testing for healthcare-associated infections is steadily increasing globally to tackle adverse events related to HAIs and take appropriate decisions on treatments. Therefore, the increase in the number of people with HAIs is encouraging physicians in hospitals to use advanced and rapid diagnostic tests, thereby contributing to the growth of the segment.

Healthcare-associated Infectious Disease Diagnostics Market: Geography

The healthcare-associated infections diagnostics market in North America is likely to witness upward growth in terms of revenue, with key vendors focusing on developing innovative and advanced infectious disease diagnostics products, which will offer efficient results. The US is the major revenue contributor to the global market due to the presence of health coverage and the availability of advanced health infrastructure. Europe accounts for the second highest market share in the global healthcare-associated infections diagnostics market. Countries such as Germany, France, the UK, Spain, Italy, and Denmark have a high occurrence rate of HAIs. According to the European Centre for Disease Control and Prevention (ECDC), approximately 9 million HAI cases occur across Europe annually. The growing demand for traditional culture-based tests and immunoassays is a major driver for the APAC market.

Key Vendor Analysis

The healthcare-associated infections diagnostics market is consolidated and is characterized by the presence of several active global, regional, and local players, offering a diverse range of diagnostic analyzers and consumables for diagnosing HAIs. Global players are focusing on developing innovative products and expanding their product portfolio to remain competitive in the market. They are investing extensively in R&D and product development activities to expand their product portfolio. Key players are also engaged in strategic acquisitions as part of the inorganic growth strategy to improve sales and profit margins. Strategic M&As continue to be an important competitive strategy for key players to expand product offerings, access new technology, or increase market share.

Key Market Insights

  • The report provides the following insights into the healthcare-associated infections diagnostics market for the forecast period 2019–2024.
  • Offers market sizing and growth prospects of the healthcare-associated infections diagnostics market for the forecast period 2019–2024.
  • Provides comprehensive insights on the latest industry trends, market forecast, and growth drivers in the healthcare-associated infections diagnostics market.
  • Includes a detailed analysis of market growth drivers, challenges, and investment opportunities.
  • Delivers a complete overview of market segments and the regional outlook of the healthcare-associated infections diagnostics market.
  • Offers an exhaustive summary of the vendor landscape, competitive analysis, and key market strategies to gain a competitive advantage in the market.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott
  • bioMérieux
  • DiaSorin Molecular
  • Hoffmann-La Roche
  • Luminex
  • Quidel
  • MORE
1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of the study
4.4 Market Segments
4.4.1 Market Segmentation by Products
4.4.2 Market Segmentation by Healthcare-associated Infections
4.4.3 Market Segmentation by Diagnostic Tests
4.4.4 Market Segmentation by End-users
4.4.5 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at a Glance

7 Introduction
7.1 Overview
7.1.1 Causative Organisms of HAIs
7.1.2 Epidemiology of HAIs

8 Market Dynamics
8.1 Market Growth Enablers
8.1.1 Technological Advancements in Diagnostic Tools & Assays for HAIs
8.1.2 Increase in Patient Population with HAIs
8.1.3 Growing Popularity of Molecular Diagnostic Tests for HAIs
8.2 Market Growth Restraints
8.2.1 Stringent Regulations to Prevent HAIs in Healthcare Settings
8.2.2 Availability of Sophisticated Mechanisms to Control HAIs
8.2.3 Low Prevalence of HAIs in High-income Nations
8.3 Market Opportunities & Trends
8.3.1 Strategic Acquisitions
8.3.2 High Growth Potential in Low and Middle-income Countries
8.3.3 Growing Penetration of POC Tests to Diagnose HAIs

9 Market Landscape
9.1 Market Overview
9.2 Market Size & Forecast
9.3 Five Forces Analysis
9.3.1 Threat of New Entrants
9.3.2 Bargaining Power of Suppliers
9.3.3 Bargaining Power of Buyers
9.3.4 Threat of Substitutes
9.3.5 Competitive Rivalry

10 By Infection Type
10.1 Market Snapshot & Growth Engine
10.2 Market Overview
10.3 Urinary Tract Infections
10.3.1 Market Overview
10.3.2 Market Size & Forecast
10.4 Surgical Site Infections
10.4.1 Market Overview
10.4.2 Market Size & Forecast
10.5 Hospital-acquired Pneumonia
10.5.1 Market Overview
10.5.2 Market Size & Forecast
10.6 BloodStream Infections
10.6.1 Market Overview
10.6.2 Market Size & Forecast
10.7 Gastrointestinal Infections
10.7.1 Market Overview
10.7.2 Market Size & Forecast
10.8 Other Healthcare-associated Infections
10.8.1 Market Overview
10.8.2 Market Size & Forecast

11 By Product Type
11.1 Market Snapshot & Growth Engine
11.2 Market Overview
11.3 Consumables
11.3.1 Market Overview
11.3.2 Market Size & Forecast
11.4 Analyzers/Instruments
11.4.1 Market Overview
11.4.2 Market Size & Forecast

12 By Test Type
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Traditional Diagnostics
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 Traditional Diagnostics Market Segmentation By Geography
12.4 Molecular Diagnostics
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Molecular Diagnostics Market Segmentation by Geography

13 By End-User Type
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Hospitals
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Clinics
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 ASCs
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Others
13.6.1 Market Overview
13.6.2 Market Size & Forecast

14 By Geography
14.1 Market Snapshot & Growth Engine
14.2 Market Overview

15 North America
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Market Segmentation by Test Type
15.4 Key Countries
15.4.1 US: Market Size & Forecast
15.4.2 Canada: Market Size & Forecast

16 Europe
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Market Segmentation by Test Type
16.4 Key Countries
16.4.1 Germany: Market Size & Forecast
16.4.2 France: Market Size & Forecast
16.4.3 UK: Market Size & Forecast
16.4.4 Spain: Market Size & Forecast
16.4.5 Italy: Market Size & Forecast

17 APAC
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Market Segmentation by Test Type
17.4 Key Countries
17.4.1 Japan: Market Size & Forecast
17.4.2 China: Market Size & Forecast
17.4.3 India: Market Size & Forecast
17.4.4 South Korea: Market Size & Forecast
17.4.5 Australia: Market Size & Forecast

18 Latin America
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Market Segmentation by Test Type
18.4 Key Countries
18.4.1 Brazil: Market Size & Forecast
18.4.2 Mexico: Market Size & Forecast

19 Middle-East & Africa
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Market Segmentation by Test Type
19.4 Key Countries
19.4.1 Turkey: Market Size & Forecast
19.4.2 South Africa: Market Size & Forecast
19.4.3 Saudi Arabia: Market Size & Forecast

20 Competitive Landscape
20.1 Competition Overview
20.2 Market Share Analysis

21 Key Company Profiles
21.1 Abbott
21.1.1 Business Overview
21.1.2 Major Product Offerings
21.1.3 Key Strengths
21.1.4 Key Strategies
21.1.5 Key Opportunities
21.2 BD
21.2.1 Business Overview
21.2.2 Major Product Offerings
21.2.3 Key Strengths
21.2.4 Key Strategies
21.2.5 Key Opportunities
21.3 bioMérieux
21.3.1 Business Overview
21.3.2 Major Product Offerings
21.3.3 Key Strengths
21.3.4 Key Strategies
21.3.5 Key Opportunities
21.4 Danaher
21.4.1 Business Overview
21.4.2 Major Product Offerings
21.4.3 Key Strengths
21.4.4 Key Strategies
21.4.5 Key Opportunities
21.5 F. Hoffmann-La Roche
21.5.1 Business Overview
21.5.2 Major Product Offerings
21.5.3 Key Strengths
21.5.4 Key Strategies
21.5.5 Key Opportunities
21.6 Meridian Bioscience
21.6.1 Business Overview
21.6.2 Major Product Offerings
21.6.3 Key Strengths
21.6.4 Key Strategies
21.6.5 Key Opportunities
21.7 QIAGEN
21.7.1 Business Overview
21.7.2 Major Product Offerings
21.7.3 Key Strengths
21.7.4 Key Strategies
21.7.5 Key Opportunities

22 Other Prominent Vendors
22.1 Trinity Biotech
22.1.1 Business Overview
22.1.2 Major Product Offerings
22.1.3 Key Strengths
22.1.4 Key Strategies
22.1.5 Key Opportunities
22.2 DiaSorin Molecular
22.2.1 Business Overview
22.2.2 Major Product Offerings
22.2.3 Key Strengths
22.2.4 Key Strategies
22.2.5 Key Opportunities
22.3 OpGen
22.3.1 Business Overview
22.3.2 Major Product Offerings
22.3.3 Key Strengths
22.3.4 Key Strategies
22.3.5 Key Opportunities
22.4 Accelerate Diagnostics
22.4.1 Business Overview
22.4.2 Major Product Offerings
22.4.3 Key Strengths
22.4.4 Key Strategies
22.4.5 Key Opportunities
22.5 Thermo Fisher Scientific
22.5.1 Business Overview
22.5.2 Major Product Offerings
22.5.3 Key Strengths
22.5.4 Key Strategies
22.5.5 Key Opportunities
22.6 Bio-Rad
22.6.1 Business Overview
22.6.2 Major Product Offerings
22.6.3 Key Strengths
22.6.4 Key Strategies
22.6.5 Key Opportunities
22.7 Luminex
22.7.1 Business Overview
22.7.2 Major Product Offerings
22.7.3 Key Strengths
22.7.4 Key Strategies
22.7.5 Key Opportunities
22.8 Quidel
22.8.1 Business Overview
22.8.2 Major Product Offerings
22.8.3 Key Strengths
22.8.4 Key Strategies
22.8.5 Key Opportunities

23 Other Vendors
23.1 Genetics Signature
23.1.1 Business Overview
23.2 Seegene
23.2.1 Business Overview
23.3 Diatherix Eurofins
23.3.1 Business Overview
23.4 Immunexpress
23.4.1 Business Overview
23.5 ResponSe Biomedical
23.5.1 Business Overview
23.6 Humor Diagnostics
23.6.1 Business Overview
23.7 Eiken Chemical
23.7.1 Business Overview
23.8 Bruker
23.8.1 Business Overview
23.9 T2 Biosystems
23.9.1 Business Overview
23.10 Hologic
23.10.1 Business Overview

24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
24.3 Quantitative Summary
24.3.1 Market by Product Type
24.3.2 Market by Test Type
24.3.3 Market by Infection Type
24.3.4 Market by End-user Type
24.3.5 Market by Geography

25 Appendix
25.1 Abbreviations

List of Exhibits
Exhibit 1 Segmentation of Global Healthcare-associated Infectious Disease Diagnostics Market
Exhibit 2 Market Size Calculation Approach 2018
Exhibit 3 Major Causes for the Spread of Healthcare-associated Infections
Exhibit 4 Technological Advancements in Diagnostic Tools & Assays for HAIs
Exhibit 5 Increase in Patient Population with HAIs
Exhibit 6 Growing Popularity of Molecular Diagnostic Tests for HAIs
Exhibit 7 Important Milestones in Molecular Diagnostics for Infectious Diseases
Exhibit 8 Comparison of Blood Culture Test Versus Molecular Diagnostic Test
Exhibit 9 Stringent Regulations to Prevent HAIs in Healthcare Settings
Exhibit 10 WHO’s Recommendations Using My 5 Moments for Hand Hygiene Approach
Exhibit 11 Important Recommendations for Healthcare Settings to Prevent HAIs
Exhibit 12 Availability of Sophisticated Mechanisms to Control HAIs
Exhibit 13 Steps Involved in Reprocessing Cycle of Sterile Supplies
Exhibit 14 Popular Equipment Used in Healthcare Settings to Control HAIs
Exhibit 15 Low Prevalence of HAIs in High-income Nations
Exhibit 16 Rate of HAIs in Europe (Per 1,000 population)
Exhibit 17 Strategic Acquisitions
Exhibit 18 High Growth Potential in Low and Middle-income Countries
Exhibit 19 Emerging Economies Witnessing Higher Absolute Growth in APAC
Exhibit 20 Emerging Economies Witnessing Higher Absolute Growth in Latin America
Exhibit 21 Growing Penetration of POC Tests to Diagnose HAIs
Exhibit 22 Global Healthcare-associated Infectious Disease Diagnostics Market 2018−2024 ($ million)
Exhibit 23 Five Forces Analysis 2018
Exhibit 24 Incremental Growth by Infection Type 2018–2024
Exhibit 25 Global HAI Disease Diagnostics Market by Infection Type
Exhibit 26 Global HAI Disease Diagnostics Market by Infection Type 2018 & 2024 (%)
Exhibit 27 Global HAI Disease Diagnostics Market by Infection Type 2018−2024 ($ million)
Exhibit 28 Global HAI Disease Diagnostics Market by Infection Type 2018−2024 (%)
Exhibit 29 Global HAI Infectious Disease Diagnostics Market by Infection Type 2018-2024 (Incremental Growth)
Exhibit 30 Global HAI Disease Diagnostics Market by Infection Type 2018-2024 (Absolute Growth)
Exhibit 31 Global HAI Diagnostics Market by UTIs: Incremental and Absolute Growth Comparison
Exhibit 32 Risk Factors with Development of Hospital-associated UTIs
Exhibit 33 Global HAI Diagnostics Market by UTIs 2018−2024 ($ million)
Exhibit 34 Hospital-acquired Bacteriuria in Patients with Indwelling Urethral Catheters (%)
Exhibit 35 Global HAI Diagnostics Market by SSIs: Incremental and Absolute Growth Comparison
Exhibit 36 Risk Factors of Surgical Site Infections
Exhibit 37 Global HAI Diagnostics Market by SSIs 2018−2024 ($ million)
Exhibit 38 Global HAI Diagnostics Market by HAP: Incremental and Absolute Growth Comparison
Exhibit 39 Common Pathogens Causing HAP
Exhibit 40 Global HAI Diagnostics Market by HAP 2018−2024 ($ million)
Exhibit 41 Host Risk Factors with Development of Multidrug-resistant Infection in HAP
Exhibit 42 Global HAI Diagnostics Market by BSI: Incremental and Absolute Growth Comparison
Exhibit 43 Global HAI Diagnostics Market by BSI 2018−2024 ($ million)
Exhibit 44 Global HAI Diagnostics Market by GII: Incremental & Absolute Growth Comparison
Exhibit 45 Global HAI Diagnostics Market by GII 2018−2024 ($ million)
Exhibit 46 Global HAI Diagnostics by Other Infections Incremental and Absolute Growth Comparison
Exhibit 47 Global HAI Diagnostics by Other Infections 2018−2024 ($ million)
Exhibit 48 Incremental Growth by Product Type 2018–2024
Exhibit 49 Global Healthcare-associated Infectious Disease Diagnostics Market by Product Type
Exhibit 50 Global Healthcare-associated Infectious Disease Diagnostics Market by Product Type 2018 & 2024 (%)
Exhibit 51 Global Healthcare-associated Infectious Disease Diagnostics Market by Product Type 2018−2024 ($ million)
Exhibit 52 Global Healthcare-associated Infectious Disease Diagnostics Market by Product Type 2018−2024 (%)
Exhibit 53 Global Healthcare-associated Infectious Disease Diagnostics Market by Product Type 2018-2024 (Incremental Growth)
Exhibit 54 Global Healthcare-associated Infectious Disease Diagnostics Market by Product Type 2018-2024 (Absolute Growth)
Exhibit 55 Global HAI Diagnostics Market by Consumables: Incremental and Absolute Growth Comparison
Exhibit 56 Market by Consumables 2018−2024 ($ million)
Exhibit 57 Global HAI Diagnostics Market by Analyzers/Instruments: Incremental and Absolute Growth Comparison
Exhibit 58 Market by Analyzers/Instruments 2018−2024 ($ million)
Exhibit 59 Incremental Growth by Test Type 2018−2024
Exhibit 60 Global Healthcare-associated Infectious Disease Diagnostics Market by Test Type
Exhibit 61 Global Healthcare-associated Infectious Disease Diagnostics Market by Test Type 2018 & 2024 (%)
Exhibit 62 Global Healthcare-associated Infectious Disease Diagnostics Market by Test Type 2018-2024 ($ million)
Exhibit 63 Global Healthcare-associated Infectious Disease Diagnostics Market by Test Type 2018-2024 (%)
Exhibit 64 Global Healthcare-associated Infectious Disease Diagnostics Market by Test Type 2018-2024 (Incremental Growth)
Exhibit 65 Global Healthcare-associated Infectious Disease Diagnostics Market by Test Type 2018-2024 (Absolute Growth)
Exhibit 66 Global Traditional HAI Diagnostics Market: Incremental and Absolute Growth Comparison
Exhibit 67 Global Traditional HAI Diagnostics Market 2018−2024 ($ million)
Exhibit 68 Global Traditional HAI Diagnostics Market 2018 & 2024 (%)
Exhibit 69 Global Traditional HAI Diagnostics Market 2018−2024 ($ million)
Exhibit 70 Global Traditional HAI Diagnostics Market 2018−2024 (%)
Exhibit 71 Global Molecular HAI Diagnostics Market: Incremental and Absolute Growth Comparison
Exhibit 72 Major Advantages of Molecular Diagnostics
Exhibit 73 Market by Molecular Diagnostics 2018−2024 ($ million)
Exhibit 74 Global Molecular HAI Diagnostics Market 2018 & 2024 (%)
Exhibit 75 Global Molecular HAI Diagnostics Market 2018−2024 ($ million)
Exhibit 76 Global Molecular HAI Diagnostics Market 2018−2024 (%)
Exhibit 77 Incremental Growth by End-user Type 2018−2024
Exhibit 78 Global Healthcare-associated Infectious Disease Diagnostics Market by End-user Type
Exhibit 79 Global Healthcare-associated Infectious Disease Diagnostics Market by End-user Type 2018 & 2024 (%)
Exhibit 80 Global Healthcare-associated Infectious Disease Diagnostics Market by End-user Type 2018-2024 ($ million)
Exhibit 81 Global Healthcare-associated Infectious Disease Diagnostics Market by End-user Type 2018-2024 (%)
Exhibit 82 Global Healthcare-associated Infectious Disease Diagnostics Market by End-user Type 2018-2024 (Incremental Growth)
Exhibit 83 Global Healthcare-associated Infectious Disease Diagnostics Market by End-user Type 2018-2024 (Absolute Growth)
Exhibit 84 Global HAI Diagnostics Market by Hospitals: Incremental and Absolute Growth Comparison
Exhibit 85 Global HAI Diagnostics Market by Hospitals 2018−2024 ($ million)
Exhibit 86 Global HAI Diagnostics Market by Clinics: Incremental and Absolute Growth Comparison
Exhibit 87 Global HAI Diagnostics Market by Clinics 2018−2024 ($ million)
Exhibit 88 Global HAI Diagnostics Market by ASCs: Incremental and Absolute Growth Comparison
Exhibit 89 Global HAI Diagnostics Market by ASCs 2018−2024 ($ million)
Exhibit 90 Global HAI Diagnostics Market by Other End-users: Incremental and Absolute Growth Comparison
Exhibit 91 Global HAI Diagnostics Market by Other End-users 2018−2024 ($ million)
Exhibit 92 Incremental Growth by Geography 2018−2024
Exhibit 93 Global Healthcare-associated Infectious Disease Diagnostics Market by Geography
Exhibit 94 Global Healthcare-associated Infectious Disease Diagnostics Market by Geography 2018 & 2024 (%)
Exhibit 95 Global Healthcare-associated Infectious Disease Diagnostics Market by Geography 2018-2024 ($ million)
Exhibit 96 Global Healthcare-associated Infectious Disease Diagnostics Market by Geography 2018-2024 (%)
Exhibit 97 Global Healthcare-associated Infectious Disease Diagnostics Market by Geography 2018-2024 (Incremental Growth)
Exhibit 98 Global Healthcare-associated Infectious Disease Diagnostics Market by Geography 2018-2024 (Absolute Growth)
Exhibit 99 HAI Diagnostics Market in North America: Incremental and Absolute Growth Comparison
Exhibit 100 HAI Diagnostics Market in North America 2018–2024 ($ million)
Exhibit 101 North America HAI Diagnostics Market by Test Type 2018 & 2024 (%)
Exhibit 102 North America HAI Diagnostics Market by Test Type 2018–2024 ($ million)
Exhibit 103 North America HAI Diagnostics Market by Test Type 2018–2024 (%)
Exhibit 104 Incremental Growth in North America 2018−2024
Exhibit 105 HAI Diagnostics Market in US 2018–2024 ($ million)
Exhibit 106 HAI Diagnostics Market in Canada 2018–2024 ($ million)
Exhibit 107 HAI Diagnostics Market in Europe: Incremental and Absolute Growth Comparison
Exhibit 108 Market in Europe 2018–2024 ($ million)
Exhibit 109 Europe HAI Diagnostics Market by Test Type 2018 & 2024 (%)
Exhibit 110 Europe HAI Diagnostics Market by Test Type 2018–2024 ($ million)
Exhibit 111 Europe HAI Diagnostics Market by Test Type 2018–2024 (%)
Exhibit 112 Incremental Growth in Europe 2018−2024
Exhibit 113 HAI Diagnostics Market in Germany 2018–2024 ($ million)
Exhibit 114 HAI Diagnostics Market in France 2018–2024 ($ million)
Exhibit 115 HAI Diagnostics Market in UK 2018–2024 ($ million)
Exhibit 116 HAI Diagnostics Market in Spain 2018–2024 ($ million)
Exhibit 117 HAI Diagnostics Market in Italy 2018–2024 ($ million)
Exhibit 118 HAI Diagnostics Market in APAC: Incremental and Absolute Growth Comparison
Exhibit 119 Market in APAC 2018–2024 ($ million)
Exhibit 120 APAC HAI Diagnostics Market by Test Type 2018 & 2024 (%)
Exhibit 121 APAC HAI Diagnostics Market by Test Type 2018–2024 ($ million)
Exhibit 122 APAC HAI Diagnostics Market by Test Type 2018–2024 (%)
Exhibit 123 Incremental Growth in APAC 2018−2024
Exhibit 124 HAI Diagnostics Market in Japan 2018–2024 ($ million)
Exhibit 125 HAI Diagnostics Market in China 2018–2024 ($ million)
Exhibit 126 HAI Diagnostics Market in India 2018–2024 ($ million)
Exhibit 127 HAI Diagnostics Market in South Korea 2018–2024 ($ million)
Exhibit 128 HAI Diagnostics Market in Australia 2018–2024 ($ million)
Exhibit 129 HAI Diagnostics Market in Latin America: Incremental and Absolute Growth Comparison
Exhibit 130 HAI Diagnostics Market in Latin America 2018–2024 ($ million)
Exhibit 131 Latin America HAI Diagnostics Market by Test Type 2018 & 2024 (%)
Exhibit 132 Latin America HAI Diagnostics Market by Test Type 2018–2024 ($ million)
Exhibit 133 Latin America HAI Diagnostics Market by Test Type 2018–2024 (%)
Exhibit 134 Incremental Growth in Latin America 2018−2024
Exhibit 135 HAI Diagnostics Market in Brazil 2018–2024 ($ million)
Exhibit 136 HAI Diagnostics Market in Mexico 2018–2024 ($ million)
Exhibit 137 HAI Diagnostics Market in MEA: Incremental and Absolute Growth Comparison
Exhibit 138 Market in MEA 2018–2024 ($ million)
Exhibit 139 MEA HAI Diagnostics Market by Test Type 2018 & 2024 (%)
Exhibit 140 MEA HAI Diagnostics Market by Test Type 2018–2024 ($ million)
Exhibit 141 MEA HAI Diagnostics Market by Test Type 2018–2024 (%)
Exhibit 142 Incremental Growth in MEA 2018−2024
Exhibit 143 HAI Diagnostics Market in Turkey 2018–2024 ($ million)
Exhibit 144 HAI Diagnostics Market in South Africa 2018–2024 ($ million)
Exhibit 145 HAI Diagnostics Market in Saudi Arabia 2018–2024 ($ million)
Exhibit 146 Global Healthcare-associated Infectious Disease Diagnostics Market: Vendors Market Shares
Exhibit 147 Abbott: R&D Expenditure 2016−2018 ($ million)
Exhibit 148 Abbott: Sales Breakdown by Segments in 2017−2018 ($ million)
Exhibit 149 Abbott: Sales Breakdown by Geography 2018 (%)
Exhibit 150 BD: R&D Expenditure 2016−2018 ($ million)
Exhibit 151 BD: Revenue by Business Segments 2017 & 2018 ($ million)
Exhibit 152 BD: Revenue Share by Geography (%)
Exhibit 153 Danaher: R&D Expenditure 2016−2018 ($ million)
Exhibit 154 Danaher: Revenue by Business Segments ($ billion)
Exhibit 155 Danaher: Percentage Share of Revenue by Geographies (%)
Exhibit 156 F. Hoffmann-La Roche: R&D Expenditure 2016−2018 ($ billion)
Exhibit 157 F. Hoffmann-La Roche: Revenue by Business Segments 2017−2018 ($ billion)
Exhibit 158 F. Hoffmann-La Roche: Revenue by Geographies (%)
Exhibit 159 Meridian Bioscience: R&D Expenditure 2016−2018 ($ million)
Exhibit 160 Meridian Bioscience: Revenue by Segments 2017−2018 ($ billion)
Exhibit 161 Meridian Bioscience: Revenue by Geography (%)
Exhibit 162 QIAGEN Revenue 2016−2018 ($ billion)
Exhibit 163 QIAGEN: R&D Expenditure 2016−2018 ($ million)
Exhibit 164 QIAGEN: Revenue by Segments 2017−2018 ($ billion)
Exhibit 165 QIAGEN: Revenue by Geographies

List of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2018
Table 3 Recent Product Approvals Related to HAI Diagnostics
Table 4 Popular Acquisitions in Hospital-acquired Infectious Disease Diagnostics Market
Table 5 Approved Diagnostic Technologies for Diagnosing Hospital-acquired UTIs
Table 6 Common Microbes Causing GI Infections
Table 7 Annual Number of Molecular Diagnostic Tests Performed for Various HAIs in 2016
Table 8 Global Healthcare-associated Infectious Disease Diagnostics Market: Vendors Ranking
Table 9 Abbott: Product Offerings
Table 10 BD: Key Product Offerings
Table 11 bioMérieux: Major Product Offerings
Table 12 Danaher: Key Product Offerings
Table 13 F. Hoffmann-La Roche: Key Product Offerings
Table 14 Meridian Bioscience: Product Offerings
Table 15 QIAGEN: Product Offerings
Table 16 Trinity Biotech: Key Product Offerings
Table 17 DiaSorin Molecular: Key Product Offerings
Table 18 OpGen: Key Product Offerings
Table 19 Accelerate Diagnostics: Key Product Offerings
Table 20 Thermo Fisher Scientific: Key Product Offerings
Table 21 Bio-Rad: Key Product Offerings
Table 22 Luminex: Key Product Offerings
Table 23 Quidel: Key Product Offerings
Table 24 Global Healthcare-associated Infectious Disease Diagnostics Market by Products ($ million)
Table 25 Global Healthcare-associated Infectious Disease Diagnostics Market by Products (%)
Table 26 Global Healthcare-associated Infectious Disease Diagnostics Market by Test Type ($ million)
Table 27 Global Healthcare-associated Infectious Disease Diagnostics Market by Test Type (%)
Table 28 Global Healthcare-associated Infectious Disease Diagnostics Market by Infection Type ($ million)
Table 29 Global Healthcare-associated Infectious Disease Diagnostics Market by Infection Type (%)
Table 30 Global Healthcare-associated Infectious Disease Diagnostics Market by End-user Type ($ million)
Table 31 Global Healthcare-associated Infectious Disease Diagnostics Market by End-user Type (%)
Table 32 Global Healthcare-associated Infectious Disease Diagnostics Market by Geography ($ million)
Table 33 Global Healthcare-associated Infectious Disease Diagnostics Market by Geography (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott
  • Becton Dickinson
  • bioMérieux
  • Danaher
  • Hoffmann-La Roche
  • Meridian Bioscience
  • Qiagen
  • Accelerate Diagnostics
  • Bio-Rad
  • DiaSorin Molecular
  • Luminex
  • OpGen
  • Quidel
  • Thermo Fisher Scientific
  • and Trinity Biotech
  • Bruker
  • Diatherix Eurofins
  • Eiken Chemical
  • Genetic Signature
  • Hologic
  • Humor Diagnostics
  • Immunexpress
  • Response Biomedical
  • Seegene
  • T2 Biosystems
Note: Product cover images may vary from those shown
Adroll
adroll